[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"food-allergy-peanut\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:food-allergy-peanut":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,74,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100640171","pathway-to-peanut-tolerance-100640171",false,"NCT07592780","Pathway to Peanut Tolerance","A Pragmatic, Open-label Study of Peanut Oral Immunotherapy in Inducing Desensitisation or Remission in Children With Food Allergy Compared to Standard Care (Strict Allergen Avoidance)","Inclusion Criteria:\n\n* Subject's parent and\u002F or guardian must be able to understand and provide informed consent.\n* Age 2 to 17 years of age\n* Either sex\n* Any race, any ethnicity\n* Have a history of sensitization \\[positive skin prick test to peanut extract as defined by wheal size at least 3mm above control OR peanut-specific IgE ≥0.35 kUA\u002FL\\]\n\nExclusion Criteria: Individuals who meet any of these criteria are not eligible for enrolment:\n\n* Any disorder in which adrenaline is contraindicated (such as hypertension or cardiac rhythm disorders)\n* History of chronic diseases requiring therapy (other than asthma, atopic dermatitis, allergic rhinitis)\n* Past or current major illness that in the opinion of the Site investigator may affect the subject's ability to participate in the study e.g. increased risk to the participant\n* Concurrent treatment with any allergen immunotherapy\n* Participation in any trials of therapeutic interventions for FA, or therapy with anti-IgE or other biologics within 1 year of enrolment\n* Current uncontrolled or moderate to severe asthma as defined by FEV1 value \\\u003C80% predicted for participants aged 7 years or older and are able to perform spirometry\n* Gastrointestinal eosinophilic disorders\n* Use of short-acting antihistamine (e.g. chlorpheniramine) within 3 days prior to open-labelled food challenge or skin testing, or medium-acting antihistamine (e.g. cetirizine, loratadine) within 5 days prior to open-labelled food challenge or skin testing\n* Use of beta-blockers, ACE inhibitors, angiotensin-receptor blockers or calcium channel blockers","ALL","2 Years","17 Years",{"count":20,"type":21},125,"ESTIMATED","INTERVENTIONAL",[24],"NA","While rigorous clinical trials have established peanut OIT as a promising therapy capable of inducing desensitization and even remission, its transition to routine clinical practice requires robust real-world evidence. Current management relies on strict avoidance, and the lack of reliable biomarkers to predict long-term success remains a significant barrier to the wider, more accessible application of OIT. Therefore, there is a critical need to evaluate peanut OIT in pragmatic, real-world settings. Such studies are essential to understand its effectiveness and safety beyond controlled trial conditions, to identify which patients benefit most, and to develop practical monitoring strategies. Generating this evidence is a crucial step toward making this treatment a viable and optimized option for the growing global population affected by peanut allergy.",[27,28],"Food Allergy in Children","Food Allergy Peanut",[30,31,32],"food allergy","peanut allergy","oral immunotherapy","RECRUITING","2026-05-15",{"date":36,"type":37},"2026-05-19","ACTUAL",{"date":39,"type":37},"2025-11-15",{"date":41,"type":21},"2029-12-31",{"name":43,"class":44},"Chinese University of Hong Kong","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100492677","phase-2-evaluating-the-safety-and-efficacy-of-oral-encapsulated-microbiota-transplantation-therapy-in-peanut-allergic-patients-100492677","NCT05695261","Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients","A Phase II Trial to Evaluate the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients","The study will enroll 24 peanut allergic patients aged 12-17 who meet the eligibility criteria in Part A and 13 subjects aged 12-17 years who meet eligibility criteria in Part B.\n\nInclusion Criteria:\n\nMale and female young adults aged 12-17 years, who meet all the following inclusion criteria, will be enrolled in the study.\n\n1. Develop dose limiting symptoms to peanut during a DPBCFC conducted in accordance with PRACTALL (Practical Issues in Allergology, Joint United States\u002FEuropean Union Initiative) guidelines at 1 mg, 3 mg, 10 mg, 30 mg, or 100 mg peanut protein (Part A only).\n2. Has a positive SPT to peanut (≥3mm) and\u002For a positive peanut-specific IgE \\>0.35kU\u002FL (Part A only).\n3. For asthmatic patients, has a Spirometry or Peak Flow with Measurement of FEV1\\>=80% of predicted\n4. Has a negative urine hCG test if a female participant.\n5. Agrees to use an acceptable single-barrier form of birth control from enrollment through the exit DBPCFC study visit if female of childbearing potential and sexually active. An example of a single-barrier method of contraception includes condoms or oral contraceptives. Acceptable methods of birth control include implants, injectables, combined oral contraceptives, some intrauterine contraceptive devises (IUDs), sexual abstinence, a vasectomized partner, the contraceptive patch, the contraceptive ring, and condoms.\n6. Able to swallow 2 empty capsules size 00.\n7. Able to give informed assent and guardian willing to give informed consent.\n8. Willing and able to participate in the study requirements, including study visits, food challenges, serial stool collection\n9. Willing to undergo telephone or email follow-up to assess for safety and adverse events.\n10. Subject has been on maintenance peanut oral immunotherapy for at least a year (part B only).\n\nExclusion Criteria:\n\nSubjects who fall into any of the following exclusion criteria at the time of screening are not eligible for enrollment into the study.\n\n1. Patients with a history of severe anaphylaxis to any food (hypotension requiring vasopressor support, hypoxia requiring mechanical ventilation, or neurological compromise)\n2. For Part A, patients with current diagnosis of an IgE mediated reactions to food (excluding allergic reactions to peanut, tree nuts, egg and milk, provided that MTT does not contain traces of these food estimated to be above the LOAEL in 5 capsules combined, and excluding oral allergy syndrome, and excluding other foods that the MTT donor avoided)\n3. For Part B, patients with current diagnosis of an IgE mediated reactions to food (excluding allergic reactions to peanut, tree nuts, egg and milk, provided that MTT does not contain traces of tree nuts, egg and milk estimated to be above the LOAEL in 4 capsules, and excluding oral allergy syndrome, excluding the food that the patient is undergoing immunotherapy to, and excluding other foods that the MTT donor avoided).\n4. Patients with chronic illness other than controlled asthma that is mild intermittent, mild- persistent or moderate persistent, mild eczema and allergic rhinitis. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment.\n5. Recurrent or chronic infections necessitating frequent systemic (including oral) antibiotic administration.\n6. Patients on chronic systemic immunosuppressive therapies.\n7. Patients who are diagnosed with active, chronic urticaria.\n8. Patients who have received peanut oral immunotherapy within the past 6 months (Part A only).\n9. Patients who are on the up-dosing phase of aeroallergen immunotherapy or patients who have received Omalizumab or dupilumab therapy within the past 6 months.\n10. Women who are pregnant or breast feeding or planning to get pregnant during the time of the study.\n11. Sexually active female patients who refuse to use contraception from enrollment through the third DBPCFC study visit\n12. Patient with GI conditions including inflammatory bowel disease, eosinophilic esophagitis, food protein induced enterocolitis, uncontrolled reflux despite medication, uncontrolled chronic constipation despite medication, esophageal dysmotility, swallowing dysfunction, delayed gastric emptying syndromes, pill esophagitis or history of aspiration pneumonia within 3 months prior to screening.\n13. Patient with current rheumatologic conditions. Exceptions can be made per PI discretion if illness is not expected to affect allergies or treatment.\n14. Patients with neutropenia \\\u003C1000 cells\u002FuL\n15. Patients participating or planning to participate in the next 6 months in interventional research trials. Exceptions can be made per PI discretion.\n16. Patients who have received systemic corticosteroids therapy for 1 week or more over the past 60 days.\n17. Patient with an allergy to Vancomycin or Neomycin or any component to the capsules.","12 Years",{"count":55,"type":21},37,[57],"PHASE2","This is a phase II trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective for Part A is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from \\\u003C=100 mg peanut protein to 300 mg after 28 days of MTT \u002Fplacebo therapy and 4 months post therapy initiation. The primary objective for Part B is to evaluate whether MTT with antibiotic pretreatment can lead to sustained unresponsiveness (SU) defined as tolerating the same dose of peanut protein administered during a food challenge at baseline and 12 weeks after OIT cessation.",[60,61,62,63,64,28],"Allergy, Peanut","Peanut Allergy","Peanut Hypersensitivity","Peanut-Induced Anaphylaxis","Food Allergy","2025-08-19",{"date":67,"type":37},"2025-08-24",{"date":69,"type":37},"2023-06-08",{"date":71,"type":21},"2027-03-01",{"name":73,"class":44},"Rima Rachid",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":45},"100536140","expecting-mothers-study-of-consumption-or-avoidance-of-peanut-and-egg-100536140","NCT06260956","Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg","ESCAPE","Inclusion Criteria:\n\n• o Subject must be able to understand and provide informed consent.\n\n* English-speaking adults, 18 years or older. (Spanish speaking adults may be included after consent document is translated and Spanish speaking study representatives are available to conduct and answer questions during informed consent process and for study follow up.)\n* Maternal consent must be provided for infants.\n* Pregnant women from the time pregnancy is confirmed until 27 weeks of gestation.\n* Self-reported at time of enrollment:\n\n  * no chronic inflammatory conditions that require long-term systemic immunosuppressive medications in first or second trimester\n  * carrying a fetus with a first-degree relative (i.e., mother, father, full sibling) with any self-reported or physician-diagnosed allergic disease (asthma, allergic rhinitis, atopic dermatitis, or food allergy).\n* Intend to give their infant their own breast milk for more than 3 months.\n* Can confidently say they have eaten PN and egg and have tolerated consumption with no food allergy reactions.\n* Willing to be randomized to consumption or avoidance diet.\n* Uncomplicated pregnancy (no gestational diabetes, no preeclampsia, no hyperemesis gravidarum), self-reported at time of enrollment.\n\nExclusion Criteria:\n\n* Inability or unwillingness of subject to give written informed consent or comply with study protocol.\n* Known history of renal\u002Fliver\u002Fcardiac insufficiency in the mother or infant.\n* Pregnant women with PN or egg allergy.\n* Pregnant women who refuse to eat PN (or peanut products) and\u002For eggs.\n* Physician diagnosed immunodeficiency in the mother or infant.\n* Current, diagnosed, mental illness or current, diagnosed, or self-reported, drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.\n* Past or current medical problems or findings from medical history that are not listed above, which, in the opinion of the investigator, may pose additional risks to the mother or infant from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.",true,"FEMALE","18 Years","40 Years",{"count":86,"type":21},500,[24],"Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.",[90,91,92,93,28],"Allergy and Immunology","Peanut and Nut Allergy","Egg Allergy","Food Allergy in Infants","2025-08-08",{"date":96,"type":37},"2025-08-13",{"date":98,"type":37},"2025-08-01",{"date":100,"type":21},"2029-09",{"name":102,"class":44},"University of Rochester",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":110,"targetDuration":17,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":45},"100530909","epap-interviewstudy-100530909","NCT06192914","EPAP, Interviewstudy","Prospective Survey of the Repeated Occurrence of Anaphylactic Reactions in Patients with Food Allergies","Inclusion Criteria:\n\n* anaphylactic reaction to peanuts, other legumes, tree nuts, seeds (e.g. sesame seed, sunflower seed), cereals (e.g. wheat, oat) or pseudocereals (e.g. quinoa)\n* participation in the European Anaphylaxis Registry (Clinical Trials Identifier: NCT05210543)\n* possibility and consent to receive links to the follow-up electronic surveys via e-mail and fill out the questionnaires electronically\n\nExclusion Criteria:\n\n* if inclusion criteria are fulfilled there are no further exclusion criteria",{"count":111,"type":21},322,"OBSERVATIONAL","The goal of this observational study is to learn about repetitive anaphylactic reactions in food allergic patients and to compare the frequency of repetitive reactions between different elicitors in food allergic patients. The main question it aims to answer are:\n\n• Is there an elicitor specific difference in the occurrence of anaphylactic reactions once the elicitor has been identified and the patient received counselling about its avoidance?\n\nParticipants will answer questionnaires via a link they will receive via e-mail at baseline and 3, 6, 12 and 24 months after inclusion in the study.",[64,28,115,116],"Allergy","Anaphylactic Shock",[64,118,119],"Repetitive Reactions","Quality of Life","2025-02-11",{"date":122,"type":37},"2025-02-13",{"date":124,"type":37},"2022-03-01",{"date":126,"type":21},"2029-02-28",{"name":128,"class":44},"Charite University, Berlin, Germany"]